Organovo Announces Phase 2 Results For FXR314; Says 'Study Subjects Receiving FXR314 Achieved Statistically Significant Reduction in Liver Fat Content From Baseline'
Organovo Announces Phase 2 Results For FXR314; Says 'Study Subjects Receiving FXR314 Achieved Statistically Significant Reduction in Liver Fat Content From Baseline'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.